Literature DB >> 23782411

Mycoplasma gallisepticum and Escherichia coli mixed infection model in broiler chickens for studying valnemulin pharmacokinetics.

X Xiao1, D H Zhao, X Yang, W Shi, H Deng, J Ma, S Zhang, Y H Liu.   

Abstract

A Mycoplasma gallisepticum-Escherichia coli mixed infection model was developed in broiler chickens, which was applied to pharmacokinetics of valnemulin in the present experiment. The velogenic M. gallisepticum standard strain S6 was rejuvenated to establish the animal model, and the wild E. coli strain O78 was injected as supplementary inoculum to induce chronic respiratory disease in chickens. The disease model was evaluated based on its clinical signs, histopathological examination, bacteriological assay, and serum plate agglutination test. The pharmacokinetics of valnemulin in infected chickens was determined by intramuscular (i.m.) injection and oral administration (per os, p.o.) of a single dose of 10 mg/kg body weight (BW). Plasma samples were analyzed by liquid chromatography-tandem mass spectrometry. The plasma concentration-time curve of valnemulin was analyzed using the noncompartmental method. After the i.m. administration, the mean values of Cmax , Tmax , AUClast , MRT, CLβ /F, Vz /F, and t1⁄2β , were 27.94 μg/mL, 1.57 h, 171.63 μg·h/mL, 4.51 h, 0.06 L/h/kg, 0.56 L/kg, and 6.50 h, respectively. By contrast, the corresponding values after p.o. administration were 5.93 μg/mL, 7.14 h, 47.60 μg·h/mL, 9.80 h, 0.22 L/h/kg, 3.35 L/kg, and 10.60 h. The disposition of valnemulin was retarded in infected chickens after both modes of extravascular administration as compared to the healthy controls. More attention should be given to monitoring the therapeutic efficacy and adverse effects of mixed infection because of higher required plasma drug concentration and enlarged AUC with valnemulin treatment.
© 2013 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23782411     DOI: 10.1111/jvp.12065

Source DB:  PubMed          Journal:  J Vet Pharmacol Ther        ISSN: 0140-7783            Impact factor:   1.786


  12 in total

1.  In vivo pharmacokinetic/pharmacodynamic profiles of valnemulin in an experimental intratracheal Mycoplasma gallisepticum infection model.

Authors:  Xia Xiao; Jian Sun; Tao Yang; Xi Fang; Dong Wu; Yan Q Xiong; Jie Cheng; Yi Chen; Wei Shi; Ya-Hong Liu
Journal:  Antimicrob Agents Chemother       Date:  2015-04-06       Impact factor: 5.191

2.  In vivo pharmacokinetic/Pharmacodynamic modeling of Enrofloxacin against Escherichia coli in broiler chickens.

Authors:  Xia Xiao; Lijie Jiang; Weixuan Lan; Yongjia Jiang; Zhiqiang Wang
Journal:  BMC Vet Res       Date:  2018-11-29       Impact factor: 2.741

3.  Co-infection of Mycoplasma gallisepticum and Escherichia coli Triggers Inflammatory Injury Involving the IL-17 Signaling Pathway.

Authors:  Zhiyong Wu; Liangjun Ding; Jiaxin Bao; Yuhao Liu; Qiaomei Zhang; Jian Wang; Rui Li; Muhammad Ishfaq; Jichang Li
Journal:  Front Microbiol       Date:  2019-11-15       Impact factor: 5.640

4.  Baicalin mitigated Mycoplasma gallisepticum-induced structural damage and attenuated oxidative stress and apoptosis in chicken thymus through the Nrf2/HO-1 defence pathway.

Authors:  Jichang Li; Zujian Qiao; Wanying Hu; Wei Zhang; Syed Waqas Ali Shah; Muhammad Ishfaq
Journal:  Vet Res       Date:  2019-10-21       Impact factor: 3.683

5.  Arachidonic acid metabolism is elevated in Mycoplasma gallisepticum and Escherichia coli co-infection and induces LTC4 in serum as the biomarker for detecting poultry respiratory disease.

Authors:  Zhiyong Wu; Chunli Chen; Qiaomei Zhang; Jiaxin Bao; Qianqian Fan; Rui Li; Muhammad Ishfaq; Jichang Li
Journal:  Virulence       Date:  2020-01-01       Impact factor: 5.882

6.  Pharmacokinetic/Pharmacodynamic Profiles of Tiamulin in an Experimental Intratracheal Infection Model of Mycoplasma gallisepticum.

Authors:  Xia Xiao; Jian Sun; Tao Yang; Xi Fang; Jie Cheng; Yan Q Xiong; Ya-Hong Liu
Journal:  Front Vet Sci       Date:  2016-09-06

7.  In Vivo Pharmacokinetic/Pharmacodynamic Profiles of Danofloxacin in Rabbits Infected With Salmonella typhimurium After Oral Administration.

Authors:  Xia Xiao; Lin Pei; Li-Jie Jiang; Wei-Xuan Lan; Jia-Yu Xiao; Yon-Jia Jiang; Zhi-Qiang Wang
Journal:  Front Pharmacol       Date:  2018-04-17       Impact factor: 5.810

8.  Up-Regulation of miR-130b-3p Activates the PTEN/PI3K/AKT/NF-κB Pathway to Defense against Mycoplasma gallisepticum (HS Strain) Infection of Chicken.

Authors:  Bo Yuan; Mengyun Zou; Yabo Zhao; Kang Zhang; Yingfei Sun; Xiuli Peng
Journal:  Int J Mol Sci       Date:  2018-07-25       Impact factor: 5.923

9.  Baicalin Attenuates Mycoplasma gallisepticum-Induced Inflammation via Inhibition of the TLR2-NF-κB Pathway in Chicken and DF-1 Cells.

Authors:  Zhiyong Wu; Chunli Chen; Yusong Miao; Yuhao Liu; Qiaomei Zhang; Rui Li; Liangjun Ding; Muhammad Ishfaq; Jichang Li
Journal:  Infect Drug Resist       Date:  2019-12-20       Impact factor: 4.003

10.  Comparisons of plasma and fecal pharmacokinetics of danofloxacin and enrofloxacin in healthy and Mannheimia haemolytica infected calves.

Authors:  Ashenafi Feyisa Beyi; Jonathan P Mochel; Géraldine Magnin; Tyler Hawbecker; Clare Slagel; Grant Dewell; Renee Dewell; Orhan Sahin; Johann F Coetzee; Qijing Zhang; Paul J Plummer
Journal:  Sci Rep       Date:  2022-03-24       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.